海思科医药集团股份有限公司关于持股5%以上股东部分股份质押的公告

Group 1 - The company announced that a significant shareholder, Ms. Fan Xiulian, has pledged part of her shares, with no major asset restructuring or performance compensation obligations involved [1] - As of the announcement date, the total pledged shares by the shareholder and their concerted parties were detailed, although specific figures were not disclosed [1] Group 2 - The company received approval from the National Medical Products Administration for its drug, Remifentanil Injection, to expand its use to pediatric populations for anesthesia induction and maintenance [3][4] - Remifentanil Injection is a novel intravenous anesthetic developed by the company, which was approved for domestic use in December 2020 and has shown significant clinical value, particularly in reducing pain response at injection sites and demonstrating good tolerance in pediatric patients [5] - The company submitted a New Drug Application (NDA) to the FDA for this product in July 2025, which is currently under review [6]